Abstract▴ The reduced-antigen combined diphtheria-tetanus-acellular pertussis vaccine
(dTpa) is intended for use as a booster dose in individuals aged≥ 4 years.▴ A single dose …

Reduced-antigen, combined diphtheria, tetanus, and three-component acellular pertussis
vaccine (Tdap; Boostrix®) is indicated for booster vaccination against diphtheria, tetanus …

Abstract▲ Boostrix® US formulation (hereafter referred to as Tdap) is a formulation of
reduced-antigen, combined diphtheria-tetanus-acellular pertussis vaccine, adsorbed onto …

Reduced-antigen, combined diphtheria, tetanus, and acellular pertactin-containing pertussis
vaccine (dTpa; Boostrix™) contains reduced quantities of the same toxoids/antigens found …

Pertussis continues to circulate in Chinese communities and older children, adolescents and
adults are sources of infection for unprotected infants. Two studies conducted in Jiangsu …

Background: The rising incidence of pertussis amongst adults and adolescents in
industrialised countries could be reduced by replacing tetanus and diphtheria (Td) boosters …

Reduced-antigen-content diphtheria-tetanus-acellular pertussis (dTpa) vaccine, Boostrix™,
is indicated for booster vaccination of children, adolescents and adults. The original prefilled …

Two clinical studies were undertaken to evaluate the immunogenicity of an adult-type dTpa
booster vaccine (Boostrix™ by GlaxoSmithKline Biologicals). Blood samples taken prior to …

Reduced-antigen-content diphtheria–tetanus–acellular-pertussis (dTpa) vaccines are
predominantly recommended for once-in-a-lifetime use. A second dTpa (Boostrix™ …

Boostrix® is a three-pertussis component, combined, reduced-antigen content tetanus,
diphtheria, and acellular pertussis (Tdap) booster vaccine administered as a single …